Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677786 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8193412 | 0.86 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL6956648 | 0.81 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL5203537 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8063904 | 0.81 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL8063898 | 0.81 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL6962469 | 0.81 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL6953718 | 0.81 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6961287 | 0.81 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6962439 | 0.81 | PTGS2 (0.75) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263467-B1 | PASTE FORMULATIONS COMPRISING SILICA | MERIAL LTD (GB) | 2006-05-31 | — | — | EP | claimed |
| EP-0863891-B1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2002-12-11 | — | — | EP | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| US-5981576-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 1999-11-09 | — | — | US | claimed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | claimed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | claimed |
| EP-1617822-A4 | TABLETS AND METHODS FOR MODIFIED RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS | YAMANOUCHI PHARMA TECH INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090081309-A1 | Stabilized Oral Suspension Formulation | LU GUANG WEI | 2009-03-26 | — | — | US | disclosed |
| US-7476744-B2 | Polymorphic crystalline forms of celecoxib | PFIZER INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1492527-B1 | PROCESS FOR PREPARING A FINELY SELF-EMULSIFIABLE PHARMACEUTICAL COMPOSITION | PHARMACIA CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1355631-B1 | ORAL FAST-MELT FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070202170-A1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-6169188-B1 | TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES | MERCK FROSST CANADA & CO. (CA) | 2001-01-02 | — | — | US | disclosed |
| US-6057319-A | CYCLOOXYGENASE-2 INHIBITORS; NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2000-05-02 | — | — | US | disclosed |
| US-6020343-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 2000-02-01 | — | — | US | disclosed |
| US-5981576-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 1999-11-09 | — | — | US | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885 |
| US-20070202170-A1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2 INHIBITOR | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 4/4885 |
| US-20090081309-A1 | Stabilized Oral Suspension Formulation | THPO, TTPA, SLC6A6 | PTGS2 1454/4885PTGS1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.